The company said, “Core revenue is expected to grow 8% to 15% compared to 2024, inclusive of revenue from SeQure Dx. SPL Program-related ...
Hosted on MSN1mon
MaxCyte: Building the Future of Cell and Gene Therapy InnovationMaxCyte Raises Q4 Guidance Driven by SPL Revenue MaxCyte sells electroporation tools and Strategic Platform License (SPLs). The net present value (NPV) of an SPL is $85 million, according to MaxCyte.
TG Therapeutics to use MaxCyte’s Flow Electroporation® technology and ExPERTâ„¢ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy ...
The deal came together about a year after a big leadership change. MaxCyte Inc. has made its first acquisition in its more than quarter-century of operation, about a year after its current CEO ...
10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever MaxCyte, Inc, a life sciences company, discovers, develops, and ...
MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell and gene therapies. Their core ExPERT ATx, sTX, GTx, and VLx tools use ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results